This study investigates the use of low-dose (0.5-0.75 mg/kg; maximum dose of 60 mg regardless
of body weight) ketamine hydrochloride injection, USP administered intramuscularly to healthy
clinicians as part of an experiential learning practice within a psychedelic-assisted therapy
(PAT) training program. The primary objective of this study is to test the hypothesis that
competencies required for mental healthcare professionals providing PAT are enhanced by
undergoing a single ketamine-assisted therapy experience, as part of a PAT training program.
Primary outcomes of this study are self-reported measures of therapeutic efficacy and
competency for providing both general and psychedelic-assisted therapy, measured at baseline
and four weeks following an academic in-person retreat with optional ketamine administration.
Secondary endpoints include measures of personality and magnitude of perceived mystical
experiences. Individual changes in scores across time will be calculated, and differences in
therapeutic efficacy and competency between clinician trainees who choose to participate in a
personal ketamine-assisted therapy session and those who do not will be assessed.